TMCnet News
Sorin Group Announces FDA Clearance and First U.S. Implant of Memo 3D ReChord(TM) Annuloplasty RingSorin Group (News - Alert) (MIL:SRN), (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the U.S. Food and Drug Administration (FDA) clearance for Memo 3D ReChord™, an innovative semi-rigid annuloplasty ring for mitral valve repair. The new Memo 3D ReChord, Sorin Group's latest innovation in mitral valve repair, incorporates an innovative chordal guide system into the existing Memo 3D ring to simplify and standardize the approach to artificial chord replacement. Memo 3D ReChord's unique design streamlines mitral repair procedures while allowing surgeons to obtain reproducible results even in advanced chordal reconstructions. Memo 3D ReChord's one-of-its-kind features include:
Steven F. Bolling, M.D., Professor of Cardiac Surgery, University of
Michigan Health System, Ann Arbor, MI who conducted the first
implantation of the ring n the United States, commented on his
experience: "The Memo 3D ReChord is simple to use with a minimal
learning curve for new users. The chordal guide system gives surgeons
more confidence when performing anterior mitral leaflet repairs with
Gore-Tex® chordae. "The Memo 3D ReChord implant performed by Prof. Bolling and his team represents the first step in strategically growing our presence in the US mitral valve repair market," said Michel Darnaud, President Cardiac Surgery Business Unit, Sorin Group. "The most gratifying aspect of this first U.S. experience is to see Sorin's technology deliver on the Company's commitment to increase product standards for physicians while improving patient outcomes."
About Sorin Group For more information, please visit www.sorin.com.
|